A phase II trial of everolimus (E) and bevacizumab (B) in advanced non-clear cell renal cell cancer (ncRCC) to show efficacy in patients (pts) with papillary features.
Martin H. Voss(Memorial Sloan Kettering Cancer Center), Darren R. Feldman(Memorial Sloan Kettering Cancer Center), Ana M. Molina(Cornell University), Almedina Redzematovic(Memorial Sloan Kettering Cancer Center), James J. Hsieh(Memorial Sloan Kettering Cancer Center), Joshua Chaim(Cornell University), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Patricia Wang(Cornell University), Sujata Patil(Kettering University), William Lee(Drexel University), Ying‐Bei Chen(Memorial Sloan Kettering Cancer Center), Kaitlin M. Woo(Cornell University), Devyn Taylor Coskey(Memorial Sloan Kettering Cancer Center)
Cited by 1
Related Papers
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.6k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k